Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne van Ryn

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Current Opinion in Drug Discovery & Development|August 29, 2002
Designing selective COX-2 inhibitors: molecular modeling approachesGuenter Trummlitz, Joanne van Ryn
Expert Opinion on Drug Discovery|May 10, 2016
The discovery of dabigatran etexilate for the treatment of venous thrombosisMartin Feuring, Joanne van Ryn
European Heart Journal. Cardiovascular Pharmacotherapy|April 3, 2020
Comments on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to doseJutta Heinrich-Nols, Joanne van Ryn
Clinics in Laboratory Medicine|August 30, 2014
Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assaysJoanne van Ryn, Oliver Grottke, Henri Spronk
The American Journal of Medicine|February 7, 2012
Interpretation of point-of-care INR results in patients treated with dabigatranJoanne van Ryn, Lawrence Baruch, Andreas Clemens
Clinical Pharmacokinetics|December 29, 2016
Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study"Stephan Glund, Paul Reilly, Joanne van Ryn, et al.
Annals of Neurology|April 23, 2015
Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to DabigatranShin-Young Na, Eva Mracsko, Joanne van Ryn, et al.
Anesthesiology|April 10, 2014
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulationJoanne van Ryn, Johanna Schurer, Monika Kink-Eiband, et al.
Thrombosis Research|February 27, 2015
Assessing the anticoagulant effect of dabigatran in children: an in vitro studyKevin Dietrich, Linda Stang, Joanne van Ryn, et al.
Critical Care (London, England)|February 7, 2014
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental modelOliver Grottke, Joanne van Ryn, Henri M H Spronk, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Current Opinion in Drug Discovery & Development|August 29, 2002
Designing selective COX-2 inhibitors: molecular modeling approachesGuenter Trummlitz, Joanne van Ryn
Expert Opinion on Drug Discovery|May 10, 2016
The discovery of dabigatran etexilate for the treatment of venous thrombosisMartin Feuring, Joanne van Ryn
European Heart Journal. Cardiovascular Pharmacotherapy|April 3, 2020
Comments on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to doseJutta Heinrich-Nols, Joanne van Ryn
Clinics in Laboratory Medicine|August 30, 2014
Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assaysJoanne van Ryn, Oliver Grottke, Henri Spronk
The American Journal of Medicine|February 7, 2012
Interpretation of point-of-care INR results in patients treated with dabigatranJoanne van Ryn, Lawrence Baruch, Andreas Clemens
Clinical Pharmacokinetics|December 29, 2016
Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study"Stephan Glund, Paul Reilly, Joanne van Ryn, et al.
Annals of Neurology|April 23, 2015
Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to DabigatranShin-Young Na, Eva Mracsko, Joanne van Ryn, et al.
Anesthesiology|April 10, 2014
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulationJoanne van Ryn, Johanna Schurer, Monika Kink-Eiband, et al.
Thrombosis Research|February 27, 2015
Assessing the anticoagulant effect of dabigatran in children: an in vitro studyKevin Dietrich, Linda Stang, Joanne van Ryn, et al.
Critical Care (London, England)|February 7, 2014
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental modelOliver Grottke, Joanne van Ryn, Henri M H Spronk, et al.
Pageof 7